Safety and Feasibility of Surgery After Conversion Therapy for Locally Advanced and Advanced NSCLC
- Conditions
- Locally Advanced CancerPulmonary NeoplasmAdvanced Cancer
- Interventions
- Procedure: Surgery
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04945928
- Locations
- 🇨🇳
Ruijin hospital, Shanghai JiaoTong University School of Medicine, Shanghai, Shanghai, China
Using Cryoballoon Ablation as Initial Treatment for Persistent Atrial Fibrillation
- Conditions
- Atrial Fibrillation, PersistentArrhythmias, Cardiac
- Interventions
- Drug: Antiarrhythmic drug including Propafenone, Sotalol, Dronedarone and AmiodaroneDevice: cryoballoon ablation
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 286
- Registration Number
- NCT04942834
- Locations
- 🇨🇳
The Second Hospital Of Tianjin Medical University, Tianjin, Tianjin, China
🇨🇳The First Affiliated Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
🇨🇳The Affiliated Hospital Of Guizhou Medical University, Guiyang, Guizhou, China
Risk Factors for Predictors of MACEs After RA-CABG
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2021-06-22
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 370
- Registration Number
- NCT04935086
- Locations
- 🇨🇳
Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai, China
Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3)
- Conditions
- Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi)
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04932187
- Locations
- 🇨🇳
Department of Oncology, Ruijin Hospital, Shanghai, China
Induction Chemotherapy Combined With Toripalimab in Locoregionally-Advanced Laryngo-Hypopharyngeal Squamous Cell Cancer
- Conditions
- Locoregionally Advanced Laryngo-hypopharyngeal Squamous Cell Cancer
- Interventions
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04926753
- Locations
- 🇨🇳
Department of Oncology, Ruijin Hospital, Shanghai, China
Super Hypofractionated Irradiation for Whole Breast Treatment
- Conditions
- Breast Cancer
- Interventions
- Radiation: External Beam radiotherapy using IMRT technique
- First Posted Date
- 2021-06-15
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 217
- Registration Number
- NCT04926766
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder Cancer
- Conditions
- Muscle-Invasive Bladder Carcinoma
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2021-06-02
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04909775
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Construction of Special Disease Cohort Database and Biological Sample Holographic Database of Severe Pneumonia
- Conditions
- Severe PneumoniaSpecial Disease Cohort DatabaseHolographic Library of Biological Samples
- First Posted Date
- 2021-05-12
- Last Posted Date
- 2021-10-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT04882436
- Locations
- 🇨🇳
Ruijin Hospital, Medical School of Shanghai Jiaotong University, Shanghai, Shanghai, China
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
- Conditions
- Peripheral T-cell Lymphoma
- Interventions
- Drug: BEAC
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2021-05-11
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 266
- Registration Number
- NCT04880746
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
Arsenic Trioxide in Refractory Solid Tumors With Rescuable p53 Mutation
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT04869475
- Locations
- 🇨🇳
Department of Oncology, Ruijin Hospital, Shanghai, China